Title
Prospective evaluation of the impact of potent antiretroviral therapy on the incidence of Kaposi's Sarcoma in East Africa: findings from the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium

Permalink
https://escholarship.org/uc/item/0sk4s5b1

Journal
Infectious Agents and Cancer, 7(Suppl 1)

ISSN
1750-9378

Authors
Martin, Jeffrey
Wenger, Megan
Busakhala, Naftali
et al.

Publication Date
2012-04-19

DOI
http://dx.doi.org/10.1186/1750-9378-7-S1-O19

Peer reviewed
Prospective evaluation of the impact of potent antiretroviral therapy on the incidence of Kaposi’s Sarcoma in East Africa: findings from the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium

Jeffrey Martin1*, Megan Wenger1, Naftali Busakhala2, Nathan Buziba2, Mwebesa Bwana3, Winnie Muyindike3, Ruth Mbabazi3, Erin Amerson1, Constantin Yiannoutsos4, Beverly Musick4, Philip LeBoit1, Timothy McCalmont1, Beth Ruben1, Toby Maurer1, Kara Wool-Kaloustian4

From 13th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies (ICMAOI)
Bethesda, MD, USA. 7-8 November 2011

Background
Prior to the rollout of potent antiretroviral therapy (ART), Kaposi’s sarcoma (KS) was the most commonly reported malignancy in many resource-limited settings, such as most of sub-Saharan Africa. In resource-replete settings (e.g., U.S. or Europe), the advent of ART—and the availability of established research networks—resulted in documentation of a marked decrease in KS incidence. In contrast, in resource-limiting settings like Africa, the heretofore lack of epidemiologic infrastructure has limited our knowledge about the effect of ART on KS incidence.

Methods
We prospectively followed HIV-infected adults, without prior KS, attending 26 HIV/AIDS clinics at the Mbarara (Uganda) or AMPATH (Kenya) sites of East Africa IeDEA. Time zero was October 2008, when we introduced skin punch biopsy for KS diagnosis, which was available same-day free of charge. Biopsies were adjudicated by board-certified UCSF dermatopathologists. Patients were followed until they developed KS, death, loss-to-follow-up, or administrative closure. Once started on ART, patients were considered on ART irrespective of adherence/interruptions. Incident KS was defined as any new occurrence of KS 30 days after clinic enrollment that was documented either pathologically or by clinical diagnosis in the absence of pathology.

Results
We followed 98,024 HIV-infected adults: 31% men, 66% ever on ART, and median values at study enrollment of 35 years old (IQR: 29-43) and 277 CD4+ T-cells/mm3 (IQR: 137-453). Patients were followed for 144,182 person-years (median 1.8 years/patient) for 499 incident KS diagnoses, 43% of which were pathologically confirmed. KS incidence during non-ART use was 1876 cases/100,000-person-years in Uganda and 596 in Kenya; incidence during ART use was 201/100,000-person-years in Uganda and 270 in Kenya. After adjustment for age and gender, ART-users had a substantially reduced rate of KS compared to non-users: 88% reduction in Uganda (p<0.001), and 50% in Kenya (p<0.001). Further adjustment by CD4+ count showed a persistent ART effect, suggesting ART benefits for KS prevention above and beyond CD4 restoration (Table). In ART-users who achieved a CD4+ count of >350 cells/mm3, KS incidence declined to 18/100,000-person-years in Uganda and 93/100,000-person-years in Kenya.
Conclusions
In a prospective study in East Africa, KS incidence was very high in untreated HIV-infected adults but was substantially reduced by ART — similar to that observed in resource-replete settings. Despite ART, absolute rates of KS remained considerable until a CD4+ count of >350 was achieved, suggesting the need for earlier ART initiation. The IeDEA platform provides unique opportunities for prospective African KS research.

Author details
1University of California, San Francisco, USA. 2Moi University, Eldoret, Kenya. 3Mbarara University of Science and Technology, Mbarara, Uganda. 4Indiana University, Indianapolis, IN, USA.

Published: 19 April 2012

Table 1

<table>
<thead>
<tr>
<th>CD4+ T cell count (cells/mm³)</th>
<th>During Time of No ART Use</th>
<th>During ART Use</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. KS cases</td>
<td>Person-years</td>
</tr>
<tr>
<td>0-50</td>
<td>19</td>
<td>645</td>
</tr>
<tr>
<td>51-100</td>
<td>2</td>
<td>613</td>
</tr>
<tr>
<td>101-200</td>
<td>8</td>
<td>1682</td>
</tr>
<tr>
<td>201-350</td>
<td>27</td>
<td>6383</td>
</tr>
<tr>
<td>&gt;350</td>
<td>23</td>
<td>13926</td>
</tr>
</tbody>
</table>

* per 100,000 person-years

Cite this article as: Martin et al. Prospective evaluation of the impact of potent antiretroviral therapy on the incidence of Kaposi’s Sarcoma in East Africa: findings from the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium. Infectious Agents and Cancer 2012, 7 (Suppl 1):O19

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit